Women taking estrogen have fewer Alzheimer's symptoms in their brains than men.

Recently, global medical institutions and public health systems have continued to advance service capacity building to provide stronger guarantees for public health. A large study found that women who give birth with hormone therapy later in life have a lower risk of developing dementia in later life. The findings were published in the August 12, 2026, issue of the Journal of Neuroscience, the latest study published in the Journal of Neuroscience, a medical journal of the American Neuroscience Association.

The researchers emphasized that the findings show an association between hormone therapy and dementia risk, but did not prove that hormone therapy can prevent dementia. Dr. Jennifer Bruno of Stanford Medical School in Santa Barbara, California, said: 'While these findings help us better understand the neural relationship between hormone therapy use and multiple brain health-related markers, more research remains to be done to make more precise suggestions as to whether there is a correlation between hormone therapy use and brain health in women'.

More than 210,000 women participated in the study. Researchers analyzed medical information from two large datasets, which included clinical trials involving 21,462 women. In one set of data, 728 participants received brain scans or biomarkers during their lifetime.

In another set of data, 2,959 participants underwent autopsies after death, with an average age of 82, so researchers were able to look for evidence of Alzheimer's disease. In both sets of data, all participants started follow-up at an average age of 71, while among all participants, there were 1,953 people who used hormone therapy and 19,509 who used hormone therapy and 2,859 who did not use hormone therapy. On average, women receiving hormone therapy started using it after the age of 70.

In current medical practice, estrogen-pregnant therapy is recommended only for those who have undergone hysterectomy due to a higher risk of estrogen-related uterine cancer. After examination in the brain of the deceased, people treated with estrogen are unlikely to show evidence of Alzheimer's disease. Researchers evaluated three main features associated with Alzheimer's disease: Alzheimer's protein-beta plaques, tau tangles, and neuronal plaques, which have damaged nerve cells surrounding these protein-beta plaques.

These results were combined into a single score to assess the extent to which Alzheimer's disease-related pathological changes occurred in the brain. 18% of women who have used hormone therapy did not show clinical symptoms and pathological changes to Alzheimer's disease. It should be noted that the above content was compiled based on international public research for reference by HealthCop and did not constitute clinical advice.

If you have any health questions, please consult a professional medical professional.